Respiratory Molecular Diagnostics Market: By Technology (Polymer Chain Reaction And Next-Generation Sequencing), By Disease Indication (Viruses, Bacteria, And Others), By End-users (Hospital, Research Institution, Point Of Care Setting, And Diagnostic Laboratories) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Respiratory Molecular Diagnostics Market is expected to grow at a compound annual growth rate (CAGR) of 7.1%. The rising prevalence of respiratory illnesses, particularly among the aging population, increased demand for advanced diagnostics with the integration of AI, data analysis, and technological advancements (imaging, molecular diagnostics, rapid tests) are fuelling the respiratory molecular diagnostics market. This growth is driven by the need for early detection, personalized treatment, and efficient response to outbreaks. Conversely, environmental pollution increases the patient pool, while the COVID-19 pandemic significantly boosted the market due to the need for accurate and rapid testing. Hospitals adopted stricter protocols to prevent cross-infection during the pandemic, leading to increased focus on respiratory diagnostics. However, the high cost of advanced technologies for diagnostics and the limited resources and awareness remain challenges and hurdles.

Respiratory Molecular Diagnostics Market Key Developments:
  • In 2023, The Alinity m Resp-4-Plex assay, a one-step test approved by the FDA, detects and differentiates between SARS-CoV-2, influenza A/B, and respiratory syncytial virus.
  • August 2, 2023, Becton, Dickinson and Company (BD) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its single molecular diagnostic combination test, BD Respiratory Viral Panel (RVP) for BD MAX System.

Respiratory Molecular Diagnostics Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Respiratory Molecular Diagnostics Market Dynamics

The respiratory molecular diagnostics market is experiencing significant growth driven by the integration of advanced technologies such as polymer chain reaction (PCR), the most widely used technology, which amplifies specific DNA or RNA sequences, allowing for the detection of pathogens even when present in low numbers, and Loop-mediated isothermal amplification (LAMP) is a relatively new and simpler technique compared to PCR, making it suitable for point-of-care applications, increased demand for rapid diagnostics after the COVID-19 pandemic, and raising awareness of respiratory diseases have fuelled the need for rapid and accurate testing and cost-effective diagnosis, and the challenges include high cost and limited awareness about advanced technologies for diagnostics can hinder the adoption of products.

Respiratory Molecular Diagnostics Market Segmentation

By Technology
  • Polymer Chain Reaction (PCR)
  • Next-generation sequencing
By Disease Indicator


  • Influenza
  • RSV
  • COVID 19
  • Parainfluenza
  • hMPV
  • Rhinovirus
  • Adenovirus


  • Chlamydophila Pneumonia
  • Mycoplasma pneumoniae
  • Bordetella Pertussis/Parapertussis/Holmesii
  • Legionella pneumoniae
By End User
  • Hospitals
  • Research Institutions
  • Point Of Care Setting

Frequently Asked Questions

The respiratory molecular diagnostics market is expected to grow a compound annual growth rate (CAGR) of 7.1%.

Abbott Laboratories (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), BD (Becton, Dickinson and Company) (US), Hologic, Inc. (US), Qiagen (Netherlands), and Seegene Inc. (South Korea)

Asia-Pacific is the fastest growing and North America is the dominant market in respiratory molecular diagnostics.

Key Features of the Reports

  • The respiratory molecular diagnostics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • Koninklijke Philips N.V. (Netherlands)
  • BD (US), Abbott (US)
  • Thermo Fisher Scientific Inc. (US)
  • GE HealthCare (US)
  • Bio-Rad Laboratories, Inc. (US)
  • BioMérieux (France)
  • Revvity, Inc. (US)
  • Seegene Inc. (South Korea),
  • Nihon Kohden Corporation (Japan)
  • Vitalograph (UK)
  • SDI Diagnostics (US)
  • ResMed Inc. (US)
  • Siemens Healthcare GmbH (Germany)
  • Cosmed (Italy), Hologic, Inc. (US)
  • Qiagen (Netherlands),
  • Vyaire (US)
  • Visby Medical, Inc (US)
  • Briota Technologies Private Limited (India)
  • Bird Healthcare (Australia)
  • Löwenstein Medical Technology (Germany)
  • ProAxsis (Northern Ireland),
  • Compumedics Limited (Australia).

Adjacent Markets